Overview

This study will compare the efficacy of telemedicine-delivered cognitive behavioral therapy for insomnia tailored for people using cannabis for sleep (CBTi-CB-TM) to telemedicine-delivered sleep hygiene education (SHE-TM) on sleep, cannabis use, and daytime functioning. We will also evaluate the effects of CBTi-CB-TM on fundamental sleep regulatory system - homeostatic sleep drive - and its association with clinical outcomes.

Eligibility

INCLUSION CRITERIA

• 21 years of age and older, the age needed to obtain full legal access to cannabis in Michigan
• self-reported chronic insomnia (nighttime symptoms of difficulty initiating and/or maintaining sleep and/or early morning awakenings on ≥3 nights for ≥3 months with daytime impairment), consistent with DSM-5 diagnosis of Insomnia Disorder
• Insomnia Severity Index (ISI) score ≥11, indicative of at least "mild" insomnia
• a positive urine drug screen (UDS) for cannabis33
• self-reported use of cannabis at least three times weekly for the past month
• stable residence (e.g., stable sleep arrangements), consistent access to Wi-Fi, and ability to travel to Ann Arbor for sleep laboratory assessments

EXCLUSION CRITERIA

• individuals who do not understand English
• individuals judged unable to provide informed consent (e.g., intoxication, mental incompetence)
• diagnosis or high suspicion of a sleep disorder other than insomnia
• lifetime diagnosis of psychotic disorder or bipolar disorder; current post-traumatic stress disorder that directly interferes with sleep
• terminal or progressive physical illness (e.g., cancer) or neurological degenerative disease (e.g., dementia)
• use of medications known to have initiated their insomnia (e.g., steroids)
• previous receipt of CBTi
• self-reported pregnancy
• self-reported regular work schedule of rotating or night (3rd) shift work.